Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium add-on to ICS/LABA in COPD
2014-000611-14Phase 4Completed
- Sponsor
- GSK
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic obstructive pulmonary disease (COPD) comparing Umeclidinium + ICS/LABA with Placebo + ICS/LABA (2 arms). Primary endpoint: Trough FEV1 on Day 85. Started May 2014; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-000611-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000611-14.